ReviewPharmaceuticals (Basel, Switzerland)2022
Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Metabolomics-guided network pharmacology and molecular modeling suggest bioactive components of Chiliadenus montanus associated with multi-target anticancer and anti-inflammatory activities.Medical oncology (Northwood, London, England) · 2026Article
- Article
- An insight into the synthetic routes for N-arylation of morpholine using metal-catalyzed and metal-free methods.Molecular diversity · 2026Review
- Enzyme-Targeted Antiproliferative Effects of Novel Indole-Acrylamide Xenobiotics Acting on Cyclooxygenase Pathways.Journal of xenobiotics · 2026Article
- Multicomponent synergistic immobilization via in-situ and dynamic exchange strategies for constructing hierarchical biopharmaceuticals.Nature communications · 2026Article
- Bioactive Potential and COX-2 Interaction ofMolecules (Basel, Switzerland) · 2026Article
- In Silico and In Vitro Insights into the Pharmacological Potential ofMolecules (Basel, Switzerland) · 2026Article
- Genomic exploration andFrontiers in bioinformatics · 2026Article
- Thiazolidinedione derivatives: emerging role in cancer therapy.Molecular diversity · 2025Review
- Effects on Oral Squamous Carcinoma Cell Lines and Their Mechanisms of Pyrazole N-Aryl Sulfonate: A Novel Class of Selective Cyclooxygenase-2 Inhibitors.International journal of molecular sciences · 2025Article
- Design, Synthesis, In Silico Docking, Multitarget Bioevaluation and Molecular Dynamic Simulation of Novel Pyrazolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.JCI insight · 2025Article
- A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells.Molecular diversity · 2025Article
- Review
- Radiosynthesis and Preclinical Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors.Veterinary sciences · 2024Article
- Article
- A Review on Indole-triazole Molecular Hybrids as a Leading Edge in Drug Discovery: Current Landscape and Future Perspectives.Current topics in medicinal chemistry · 2024Review
- Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a serious threat to human beings and is the second-largest cause of death all over the globe. Chemotherapy is one of the most common treatments for cancer; however, drug resistance and severe adverse effects are major problems associated with anticancer therapy. New compounds with multi-target inhibitory properties are targeted to surmount these challenges. Cyclooxygenase-2 (COX-2) is overexpressed in cancers of the pancreas, breast, colorectal, stomach, and lung carcinoma. Therefore, COX-2 is considered a significant target for the synthesis of new anticancer agents. This review discusses the biological activity of recently prepared dual anticancer and COX-2 inhibitory agents. The most important intermolecular interactions with the COX-2 enzyme have also been presented. Analysis of these agents in the active area of the COX-2 enzyme could guide the introduction of new lead compounds with extreme selectivity and minor side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.